Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320276 | PMC |
| http://dx.doi.org/10.21037/jtd-24-222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Facts and hopes in neoadjuvant immunotherapy combinations in resectable non-small-cell lung cancer.
Clin Cancer Res
January 2025
University Hospital Essen, Essen, Germany.
Antibodies targeting immune checkpoints, such as PD-1, PD-L1, or CTLA-4, have transformed the treatment of patients with lung cancers. Unprecedented rates of durable responses are achieved in an imperfectly characterized population of patients with metastatic disease. More recently, immune checkpoint inhibitors have been explored in patients with resectable non-small-cell lung cancers.
View Article and Find Full Text PDFSpatial biology captures the effects of neoadjuvant chemo-immunotherapy in lung cancer.
Nat Genet
December 2024
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
Prognosis prediction using significant pathological response following neoadjuvant immunotherapy in resectable non-small-cell lung tumors: a meta-analysis.
Front Surg
November 2024
Thoracic Oncology Surgery Department, Baotou Cancer Hospital, Baotou, Inner Mongolia, China.
Background: A meta-analysis study was done to figure out how to predict the prognosis of people with resectable non-small-cell lung cancer (NSCLC) who had a significant pathological response following neoadjuvant immunotherapy.
Methods: Up until August 2024, a comprehensive literature study was completed, and 2,386 connected studies were revised. The 35 selected studies included 3,118 resectable non-small-cell lung tumor participants at the beginning of the study.
[Neoadjuvant chemoradiotherapy versus neoadjuvant chemo-immunotherapy for locally advanced esophageal squamous cell carcinoma].
Zhonghua Zhong Liu Za Zhi
November 2024
Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou310022, China.
To compare the clinical efficacy of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemo-immunotherapy (nCIT) for locally advanced esophageal squamous cell carcinoma (ESCC). Clinical data of patients who received nCRT or nCIT followed by esophagectomy for locally advanced ESCC between January 2010 and December 2022 were retrospectively collected from Zhejiang Cancer Hospital, with 155 patients in the nCRT group and 470 patients in the nCIT group. Propensity score matching (PSM) was performed in the two groups.
View Article and Find Full Text PDFThe efficacy of neoadjuvant immune checkpoint inhibitors in lung squamous cell carcinoma and adenocarcinoma: a systematic review and single-arm meta-analysis.
J Thorac Dis
October 2024
Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Background: Neoadjuvant immunotherapy is effective in treating resectable non-small cell lung cancer (NSCLC) but shows different responses in lung squamous cell carcinoma (SCC) and adenocarcinoma (ADC). Current studies are limited in size, necessitating further research to clarify these differences. This study aims to investigate whether there is a difference between the efficacy of neoadjuvant immune checkpoint inhibitors (ICIs) on lung SCC ADC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!